Bristol-Myers Squibb to buy Celgene in $74-billion bet on cancer drugs

Bristol-Myers Squibb has agreed to acquire Celgene Corp. in a $74-billion cash-and-stock deal that unites two makers of cancer drugs in one of the largest mergers of pharmaceutical companies ever. Under the terms of the proposed deal, Celgene shareholders will receive one Bristol-Myers Squibb share...